StockData
STERIS plc logo

STERIS plc (STE) KPIs and segments

STENYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 19/300% above fair value
$257.41−4.50 (-1.72%)

Close on Nov 17, 2026Market cap $25.10BP/E 31.5Yield 0.96%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Steris · năm tài chính kết thúc ngày 31 tháng 3

Nhìn nhanh KPI của Steris: 38 chỉ số vận hành, trong đó có Total Capital Equipment Backlog, Remaining Performance Obligations và Constant Currency Organic Growth — Consolidated, lấy từ 137 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của Steris kết thúc ngày 31 tháng 3 — Q2 FY27 = CQ3 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 FY27
Q1 FY27
Q4 FY26
Q3 FY26
Q2 FY26
Q1 FY26
Q4 FY25
Q3 FY25
Q2 FY25
Q1 FY25
Q4 FY24
Q3 FY24
Healthcare($M)3
1,0481,1361,0641,0349751,057976944901916
Service revenues($M)
426423405400389386363353343320
Consumable revenues($M)
392376387374359353358342343329
Capital equipment revenues($M)
231337272259227318255250215267
Applied Sterilization Technologies($M)2
298289287282281274258257250251235
Service revenues($M)
296283276279280258253248249244230
Capital equipment revenues($M)
1.406.1010.22.101.601658.801.106.635.24
Life Sciences:($M)3
147146145135149136128129161147
Consumable revenues($M)
81.575.977.275.376.168.772.169.870.460.1
Service revenues($M)
3436.535.833.336.536.632.832.246.041.7
Capital equipment revenues($M)
31.333.331.926.636.931.12326.544.244.8
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1
Service($M)
756743717715701680652633623633591
Product($M)
737845779745691801718696656786707
United States($M)
1,0911,1461,0871,0751,0261,0791,0039809471,036950
Other locations($M)
373382343344
Other foreign locations($M)
358343364344327310361328
Ireland($M)
2931.926.727.322.538.224.122.822.222.719.6
Healthcare($M)
260283260236280228217
Applied Sterilization Technologies($M)
143131129128137122116110118
Life Sciences:($M)
61.861.859.958.758.152.6
Segment operating income($M)
343337320295285304
Healthcare($M)
258260247228217224
Applied Sterilization Technologies($M)
129128116110118105
Life Sciences:($M)
61.859.958.153.752.656.7
Corporate($M)
-106-110-101-97.1-102-81.6
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1
Healthcare($M)
459479448442417458424403390
Applied Sterilization Technologies($M)
158147146142151135130123134
Life Sciences:($M)
80.780.278.677.275.570.569.6
Product($M)
369389361355331368347327316325323
Service($M)
315309295291297274264252257258237
Remaining performance obligations (RPO)($M)
1,5411,8901,9261,8241,6761,6271,5001,555
Total Capital Equipment Backlog($M)2
549554491542541515453520481434425534
Healthcare Capital Equipment Backlog($M)
456444392429428404369435405362354449
Life Sciences Capital Equipment Backlog($M)
93.411098.711311411183.785.175.672.271.485
Remaining Performance Obligations (Contracted Pipeline)($M)4
1,5351,5411,3661,8901,9261,8241,6581,6761,6271,5001,4201,555
Share Expected to Recognize Within 12 Months(%)
58.0%58.0%56.0%54.0%53.0%53.0%51.0%53.0%54.0%53.0%56.0%56.0%
Share Expected to Recognize in Years 2–3(%)
31.0%32.0%35.0%37.0%38.0%39.0%40.0%36.0%37.0%38.0%33.0%32.0%
Current Deferred Service & Maintenance Contract Liabilities($M)
61.861.159.158.849.551.857.58072.669.370.590.4
Revenue Recognized from Beginning Deferred Contract Liabilities($M)
1333.41938.57.405.606.1046-3.505.90
Constant Currency Organic Growth — Consolidated(%)5
8.1%6.2%5.0%7.8%8.9%7.8%5.9%6.2%7.0%5.6%10.0%
Organic Growth (Excluding M&A)(%)
8.0%6.8%7.1%9.2%9.9%8.7%5.0%6.3%7.2%5.4%11.0%
Reported U.S. GAAP Revenue Growth(%)
8.8%7.3%7.3%9.2%9.9%8.7%4.3%5.6%7.3%8.1%14.8%
Acquisitions Revenue Contribution($M)
11.36.902.400000011.44145.3
Prior-Year Divestitures Revenue Impact($M)
000000-10-7.80-8.90-7.900
Foreign Currency Translation Revenue Impact($M)
-1.108.4031.518.412.711.8-11.70.402.10-2.9012.4
Healthcare — Constant Currency Organic Growth(%)4
7.4%6.4%5.7%8.2%9.0%7.6%5.6%6.5%7.1%5.2%8.5%12.4%
Healthcare — Organic Growth (Ex-M&A)(%)
7.5%6.9%7.2%9.0%9.5%8.2%4.9%6.5%7.2%5.1%8.8%13.2%
Healthcare — Reported GAAP Growth(%)
8.6%7.6%7.5%9.0%9.5%8.2%4.9%6.5%8.5%10.1%13.9%19.1%
Healthcare — Acquisitions Contribution($M)
11.36.902.400000011.4414545.3
Healthcare — Foreign Currency Impact($M)
0.604.2016.37.804.904.60-7.50-0.200.70-1.202.806.30
Applied Sterilization Technologies (AST) — Constant Currency Organic Growth(%)4
5.3%4.7%1.6%7.9%7.4%10.2%10.3%9.5%8.7%7.7%4.6%4.0%
AST — Organic Growth (Ex-M&A)(%)
5.0%5.8%5.6%11.0%9.7%12.6%9.2%9.9%9.2%7.2%4.9%5.8%
AST — Reported GAAP Growth(%)
5.0%5.8%5.6%11.0%9.7%12.6%9.2%9.9%9.2%7.2%4.9%5.8%
AST — Acquisitions Contribution($M)
000000000000
AST — Foreign Currency Impact($M)
-13.2011.185.805.90-2.800.901.20-1.300.604
Life Sciences — Constant Currency Organic Growth(%)4
18.1%7.9%6.2%5.0%11.7%4.2%0.1%-1.5%3.0%4.3%1.6%19.7%
Life Sciences — Organic Growth (Ex-M&A)(%)
17.7%8.6%9.0%6.9%13.3%5.2%-0.8%-1.7%3.0%4.0%2.0%20.9%
Life Sciences — Reported GAAP Growth(%)
17.7%8.6%9.0%6.9%13.3%5.2%-6.9%-6.9%-3.9%-2.2%2.0%20.9%
Life Sciences — Acquisitions Contribution($M)
000000000000
Life Sciences — Foreign Currency Impact($M)
-0.700.904.202.6021.30-1.30-0.300.10-0.400.701.40
Total Recurring Stream (Consumables + Service)($M)2
1,2681,2301,2011,1811,1671,1361,1101,0801,0471,0371,037981
Consumables($M)
496474458463452435430428414414404390
Capital Equipment Installations($M)
321263387316294256371291282242383317
Healthcare — Total Recurring Stream (Consumables + Service)($M)
852818799792774747739721695687676649
Life Sciences — Total Recurring Stream (Consumables + Service)($M)
122116119113113109113105105102116102
Geographic Mix — United States Share of Revenue(%)2
74.0%73.0%72.0%73.0%74.0%74.0%73.0%73.0%73.0%74.0%73.0%73.0%
International Share of Revenue (Outside U.S. & Ireland)(%)
24.0%25.0%26.0%26.0%24.0%24.0%25.0%25.0%25.0%24.0%25.0%25.0%
Ireland Share of Revenue(%)
2.0%2.0%2.0%2.0%2.0%2.0%2.0%2.0%2.0%2.0%2.0%2.0%
Full-Year Guidance — Constant Currency Organic Growth (Low)(%)1
6.0%6.0%6.0%8.0%7.0%8.0%6.0%6.0%7.0%6.0%6.0%10.0%
Full-Year Guidance — Constant Currency Organic Growth (High)(%)
7.0%7.0%7.0%8.0%8.0%8.0%6.0%6.0%7.0%6.0%7.0%10.0%
Full-Year Guidance — Adjusted Diluted EPS (Low)($)3
11.3511.1011.1010.1510.159.909.909.059.059.059.058.60
Full-Year Guidance — Adjusted Diluted EPS (High)($)
11.5511.3011.3010.3010.3010.1510.159.159.259.259.258.70
Full-Year Guidance — GAAP Diluted EPS (Low)($)
8.928.9297.978.047.797.826.666.706.706.555.35
Full-Year Guidance — GAAP Diluted EPS (High)($)
9.129.129.208.128.198.048.076.766.906.906.755.45
Full-Year Guidance — Free Cash Flow($M)2
800800850850850820770700700700700685
Full-Year Guidance — Operating Cash Flow($M)
1,2501,2501,2251,2251,2251,1951,1451,0601,0601,0601,060995
Full-Year Guidance — Capital Expenditures($M)
450450375375375375375360360360360310
Adjusted Non-GAAP Diluted EPS (Continuing Operations)($)3
2.942.592.832.532.472.342.742.322.142.032.412.09
Adjusted Non-GAAP Gross Profit($M)
720686700657647630657612581577604567
Adjusted Non-GAAP Net Income($M)
287254278251245232271229213202241208
Adjusted Effective Income Tax Rate(%)
25.3%25.9%25.4%24.2%24.5%23.5%23.5%24.5%22.7%21.3%21.4%22.3%
Gamma Sterilization Decommissioning — Noncurrent Asset Retirement Obligations (AROs)($M)1
14.914.814.714.814.614.613.813.413.913.213.113.2
Current Asset Retirement Obligations (AROs)($M)
0.500.500.500.600.600.600.600.600.600.500.500.50
Finished Goods Inventory($M)3
427415355384380374335367389372374492
Raw Materials Inventory($M)
254247225237231223213230236257246304
Work-in-Process Inventory($M)
9590.190.792.989.689.583.194.310711198.3118
Inventory Excess & Obsolescence Valuation Reserves($M)
39.140.439.440.241.645.149.841.542.642.143.958
Installed-Base Product Warranty Accrual Balance($M)2
14.715.317.5171616.116.314.71514.615.415
New Product Warranties Issued($M)
3.902.305.705.504.804.904.3053.504.30
Warranty Claim Settlements & Repairs($M)
4.604.405.304.4055.104.504.604.303.40
Ethylene Oxide (EO) & Legal Contingencies Accrual($M)2
043.243.243.243.243.248.20
Restructuring Accrual Balance($M)
8.904.607.1010.813.116.218.417.721.821.40.70
Accounts Receivable Allowance for Doubtful Accounts($M)
31.829.927.329.127.125.624.422.424.523.72328
Total Statutory Employee Compensation & Benefit Costs2
Current Accrued Employee Compensation Liabilities($M)
157153221188168155193161147149165179
Unrecognized Share-Based Compensation Expense($M)
6785.942.654.670.188.451.160.475.99460.168.7
FDA 510(k) Premarket Clearances — STERIS & Acquired Subsidiaries3
040015352459
U.S. Medical Device Industry — Total FDA 510(k) Clearances
856923756806797886736856767793713877
FDA Medical Device Recall Events — STERIS & Subsidiaries (All Classes)
031220004031
FDA Recall Enforcement Reports — STERIS & Subsidiaries
031220004040
FDA MAUDE Adverse Event Reports (MDRs) — STERIS Devices4
16115914714515215313913411683100134
MAUDE Device Malfunction Reports — STERIS
1031581451431501521361311158299132
MAUDE Patient Injury Reports — STERIS
5812221331101
MAUDE Death Reports — STERIS
000000000000
U.S. Medical Device Industry — Total MAUDE MDR Reports
1,189,695923,529811,618751,012819,444632,296685,251709,498699,798631,546586,309573,619
U.S. Federal Contract Obligations Awarded to STERIS($M)
95.892.566840.018331.013826.310929.836.728.4
U.S. PPI — Surgical Appliance & Supplies Manufacturing (NAICS 339113, Index)1
U.S. Hospital Industry Total Quarterly Revenue (Census QSS)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Consolidated Revenue($M)5
1,5891,4931,5881,4961,4601,3911,4811,3711,3291,2801,4191,298
Gross Profit($M)
711684697656646628641610579572583560
Operating Income (GAAP)($M)
294286317273266246216245220186220227
Research & Development Expense($M)
31.528.628.829.528.226.427.627.42725.627.525.3
Selling, General & Administrative Expense($M)
366370352352350354334336329336309308
Net Income Attributable to Shareholders($M)
214200220193192177146174150145-1.40141
Operating Cash Flow($M)1
289367335298288420261333251304255291
Capital Expenditures($M)
76.187.590.298.786.593.670.989.210210891.5119
Total Assets($M)7
10,71410,73610,73710,59110,41110,40510,14710,00810,24210,10911,06411,435
Cash & Cash Equivalents($M)
531482440424319280172155172198207196
Inventories, Net($M)
737712632674659641581650689699675856
Property, Plant & Equipment, Net($M)
2,1882,1722,1612,1332,0922,0551,9571,9221,9301,8341,7651,845
Goodwill($M)
4,1794,1894,1954,2324,2154,2234,0964,0444,1514,0574,0714,112
Acquired Intangible Assets, Net($M)
1,4971,5641,6201,6921,7491,8171,8541,9232,0042,0492,1192,987
Long-Term Indebtedness($M)
1,6501,6501,8131,8981,8971,9031,9192,0392,1562,2363,1203,231
Total Shareholders' Equity($M)
7,2577,2077,1847,1557,0096,9576,6036,4166,5946,3556,3026,415

13 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • STERIS plc operates on a fiscal year ending March 31 (for example, FY2026 ended March 31, 2026; Q1 FY2027 ended June 30, 2026; Q2 FY2027 ended September 30, 2026).
  • Primary operational metrics focus on: (1) Capital Equipment Backlog ($548.9M at Q2 FY2027 across Healthcare and Life Sciences) and multi-year Remaining Performance Obligations ($1,535.0M); (2) Constant Currency Organic Growth and M&A/FX revenue bridges across Consolidated, Healthcare, Applied Sterilization Technologies (AST), and Life Sciences; and (3) the installed-base Recurring revenue model (Consumables + Sterilization/Maintenance Service vs. Capital Equipment) across consolidated operations and each segment.
  • All growth rates, shares, non-GAAP reconciliations, and segment figures are directly reported by STERIS plc; no ratios, margins, sums, or growth rates are computed. The only derived cells are cumulative period splits from year-to-date cash flow and footnote tables (Q4 = full year − nine months; quarterly = year-to-date − prior year-to-date). Prior-period continuing-operations figures reflect STERIS's retrospective reclassification of the divested Dental segment as discontinued operations.

Không hiện vì thiếu các kỳ gần đây (9)

  • Global AST Sterilization Facility Count ('over 60 owned or leased facilities' in Form 10-K Item 2) — excluded because management reports only an open-ended lower bound rather than a point count
  • Countries with Operating Locations ('more than 35 other countries' in Form 10-K Item 2) — excluded because disclosed only as an open-ended bound
  • Global Year-End Headcount in Form 10-K FY2022–FY2024 ('over 16,000' / 'just over 17,000') — excluded as bound phrasing; exact statutory average employee counts by segment (17,937 in FY2026) are included instead
  • STERIS Solutions Limited UK Carbon Reduction Plan GHG Emissions (PPN 06/21) — excluded because a FY2024 organizational boundary recalculation broke comparability with FY2023 (Scope 1 changed from 576.5 tCO2e to 16.1 tCO2e), leaving only 2 comparable years (FY2024–FY2025) under the revised boundary
  • STERIS Instrument Management Services Limited & Synergy Health Sterilisation UK Limited PPN 06/21 Carbon Reduction Plans — excluded because only single-year FY2024 submissions were publicly available (<3 consecutive periods)
  • Employee Pulse Engagement Survey Participation Rate (88% in FY2025, 87% in FY2026) — excluded because the global pulse survey launched in FY2025 with only 2 annual observations (<3 periods)
  • Dental Segment Revenue, Operating Income & Headcount — excluded from continuing series following the divestiture of the Dental business in Q1 FY2025
  • Quarterly Price Realization (in basis points) & Gross Tariff Cost Impact ($M) — mentioned selectively in earnings call remarks starting FY2026 without a continuous multi-year quarterly series
  • FDA Premarket Approvals (PMA) for STERIS — zero PMA filings across recent periods because STERIS's sterilization and surgical products are cleared via the 510(k) pathway

Dữ liệu cập nhật 2026-11-14.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Steris

See a number that looks wrong?